IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden talked with Proactiv's Stephen Gunnion about the company’s new collaboration with Medidata and how it supports IXICO’s growth strategy in the clinical trials space. Goorden described the agreement as a significant milestone, highlighting Medidata’s position as “a multibillion dollar player in the clinical trial space” with a global footprint across thousands of trials. The partnership combines Medidata’s electronic data capture and clinical trial t ...

Core Insights - Precigen's PAPZIMEOS therapy for adult recurrent respiratory papillomatosis (RRP) has received early and full approval, positioning it as the standard-of-care first-line treatment [4][5] - The company anticipates Q1 2026 revenue from PAPZIMEOS to exceed $18 million, reflecting strong interest from physicians and patients [3][8] - Precigen reported a net loss of $429.6 million for 2025, primarily due to non-cash items, but expects to reach cash-flow breakeven by the end of 2026 [6][16] Commercial Performance - The company has seen a rapid ramp in early commercial demand for PAPZIMEOS, with Q4 2025 net product revenue reported at $3.4 million [4][8] - The patient support hub has grown to over 300 patients, and payer coverage has expanded to approximately 215 million lives, covering nearly 90% of insured U.S. lives [7][10] - The assignment of a permanent J-code effective April 1 is expected to streamline provider workflow and improve reimbursement processes [12][14] Financial Overview - Precigen's total revenue for 2025 was $9.7 million, up from $3.8 million in 2024, driven by the launch of PAPZIMEOS [15] - The company ended 2025 with $100.4 million in cash and equivalents, which is expected to support operations until reaching cash-flow breakeven [16] - The gross-to-net revenue expectation is in the high teens to low 20% range, consistent with revenue recognized to date [17] Future Plans - Precigen plans to initiate a pediatric RRP clinical trial for PAPZIMEOS in Q4 of this year and is pursuing geographic expansion [18] - The company is also working on a marketing authorization application to the EMA and plans to sponsor activities for RRP Awareness Day in June [19]

Core Insights - Oragenics, Inc. is a clinical-stage biotechnology company focused on brain-targeted therapeutics using proprietary intranasal delivery technology [3] - The company’s lead candidate, ONP-002, is in Phase IIa clinical development for treating concussion and mild traumatic brain injury (mTBI), which affects approximately 69 million people globally each year without any approved pharmacological treatment [3] - The company received an unqualified audit opinion from its independent accounting firm regarding its financial statements, which included a paragraph about its ability to continue as a going concern [1] Financial Information - The audited consolidated financial statements for the fiscal year ended December 31, 2025, were filed on March 16, 2026, with the Securities and Exchange Commission [1][2] - The announcement regarding the audit opinion is made in compliance with NYSE American LLC Company Guide Section 610(b) [1] Company Overview - Oragenics is exploring the expansion of its central nervous system (CNS) pipeline strategy through both internal development and strategic business development [3] - The company’s intranasal delivery platform aims to provide rapid, non-invasive delivery of therapeutics directly to the brain, bypassing the blood-brain barrier [3]

Market Overview - The stock market experienced a rally driven by optimism regarding a potential truce with Iran, with mining, gold, and biotech stocks outperforming [1]. - The Russell 2000 index led the gains, increasing by 1.2%, while the Nasdaq composite initially rose by 1.5% but ultimately reduced its gains by half by the market close [1]. Key Stocks to Watch - The S&P 500 index rose but encountered resistance levels, indicating potential challenges for further upward movement [3]. - Specific stocks such as Marvell, Woodward, and BWX Technologies are highlighted as being in focus amid the current market conditions [3]. - Merck's $6.7 billion takeover of Terns is noted as a potential challenge, suggesting scrutiny over the deal's implications [3].

Financial Data and Key Metrics Changes - For the year ended December 31, 2025, total revenue was $9.7 million, a significant increase of $5.8 million or 149% compared to $3.8 million in 2024, primarily driven by the launch of PAPZIMEOS [12][13] - Net product revenue for Q4 2025 was $3.4 million, with expectations for Q1 2026 revenues to exceed $18 million based on early commercial activity [4][14] - The net loss attributable to common shareholders was $429.6 million or $1.37 per share, which included non-cash items totaling $318.5 million [16][17] Business Line Data and Key Metrics Changes - The launch of PAPZIMEOS has transitioned the company from an R&D focus to a revenue-generating commercial biotech entity, marking a pivotal milestone [3] - The number of patients in the Precigen patient support hub increased from over 200 in mid-January to well over 300, indicating strong demand for PAPZIMEOS [9][10] Market Data and Key Metrics Changes - Payer coverage for PAPZIMEOS expanded from approximately 170 million lives in early January to about 215 million, covering nearly 90% of insured lives in the U.S. [10] - The publication of an expert consensus paper in January positioned PAPZIMEOS as the first choice for adult patients with RRP, reflecting strong support from the medical community [11] Company Strategy and Development Direction - The company is actively pursuing geographic expansion, including a marketing authorization application to the EMA for PAPZIMEOS, with positive feedback from European thought leaders [18][19] - Plans to initiate a clinical trial for PAPZIMEOS in pediatric RRP patients are underway, with hopes to start in Q4 2026 [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong uptake of PAPZIMEOS, with expectations for continued revenue growth and institutional activation [12][14] - The assignment of a permanent J-code from April 1 is anticipated to streamline the reimbursement process and enhance patient access to PAPZIMEOS [28][34] Other Important Information - Research and development expenses decreased by 22.1% due to strategic prioritization, while selling, general, and administrative expenses increased by 69.8% due to PAPZIMEOS commercial activities [15] - The company ended the year with $100.4 million in cash equivalents and investments, which is expected to fund operations through cash flow breakeven by the end of 2026 [17] Q&A Session Summary Question: Can you help us think about the flow of patients from the hub to receiving reimbursed drug? - Management indicated that there is significant conversion of patients from the hub, and they aim for the majority of patients to receive treatment [24][26] Question: Are patients starting to get their second dose in the treatment regimen? - Management confirmed that patients are progressing through their treatment regimens, including those who started last year [27] Question: How is the J-code helping in terms of adding more patients? - The J-code simplifies the workflow and billing process, increasing certainty and speed for patient processing [34] Question: Can you clarify on the $18 million revenue guidance? - The $18 million guidance refers only to PAPZIMEOS product revenue, excluding other revenue sources [45] Question: What differentiates community sites that become repeat prescribers? - Management noted that community interest in PAPZIMEOS has been strong, and they have implemented logistics solutions to facilitate uptake [54][55] Question: What is the current channel mix of U.S. payers? - The payer mix is approximately 60%-65% commercial, with the remainder from Medicare and Medicaid [57]

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, totaled $9.7 million, an increase of $5.8 million or 149% compared to $3.8 million in 2024, primarily driven by the commencement of PAPZIMEOS product revenue [12][13] - Net product revenue for Q4 2025 was $3.4 million, with expectations for Q1 2026 revenues to exceed $18 million based on commercial activity to date [4][14] - The net loss attributable to common shareholders was $429.6 million or $1.37 per share for the year ended December 31, 2025, including non-cash items totaling $318.5 million [16][17] Business Line Data and Key Metrics Changes - The launch of PAPZIMEOS represents a significant transition from an R&D company to a product revenue-generating commercial biotech company [3] - The number of patients in the Precigen patient support hub grew from over 200 in mid-January to well over 300, indicating strong demand for PAPZIMEOS [9][10] - Payer coverage expanded from approximately 170 million lives in early January to about 215 million, covering nearly 90% of insured lives in the U.S. [10] Market Data and Key Metrics Changes - The FDA granted full approval for PAPZIMEOS with a broad label for adult RRP, which has led to strong interest from both patients and physicians [5][6] - The publication of an expert consensus paper positioned PAPZIMEOS as the first choice for adult patients with RRP, enhancing its market acceptance [11] Company Strategy and Development Direction - The company is actively advancing plans for a clinical trial of PAPZIMEOS in the pediatric RRP population, with hopes to initiate this in Q4 2026 [18] - Geographic expansion efforts are underway, including the validation of the marketing authorization application to the EMA for PAPZIMEOS [18] - The company aims to transition the management of RRP from surgical interventions to therapeutic management, reflecting a significant shift in treatment strategy [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong uptake of PAPZIMEOS and the anticipated revenue growth, indicating a robust launch trajectory [14][16] - The assignment of a permanent J-code from April 1 is expected to streamline the reimbursement process and enhance patient access to PAPZIMEOS [28][34] - Management highlighted the importance of payer coverage and institutional activation in driving patient treatment and revenue growth [25][36] Other Important Information - The company ended the year with $100.4 million in cash equivalents and investments, which is expected to fund operations through cash flow breakeven by the end of 2026 [17] - The company continues to advance the PRGN-2009 program, which targets HPV 16 and 18 associated cancers [19] Q&A Session Summary Question: Flow of patients from the hub to receiving reimbursed drug - Management indicated that there is significant conversion of patients from the hub and that the goal is to ensure the majority of patients receive treatment [24][26] Question: Patients starting to get their second dose - Management confirmed that patients are moving through their treatment regimens, including receiving second doses as needed [26][27] Question: Impact of the J-code on patient flow - The J-code is expected to simplify the workflow and billing process, increasing the speed at which patients are processed [34] Question: Clarification on $18 million revenue guidance - The $18 million guidance refers only to PAPZIMEOS product revenue, excluding other revenue sources [45] Question: Community uptake and differentiating factors - Management noted that community sites are showing significant interest and that logistics support is aiding in their adoption of PAPZIMEOS [54][55] Question: Current channel mix of U.S. payers - The payer mix is approximately 60%-65% commercial, consistent with prior expectations [57]

Tivic Health Systems (NasdaqCM:TIVC) Q4 2025 Earnings call March 25, 2026 04:30 PM ET Company ParticipantsLisa Wolf - CFOMichael Handley - CEOOperatorWelcome to Tivic's conference call to discuss fiscal year and fourth quarter 2025 financial results. This call has been pre-recorded. This call is being webcast, and the replay will be available on the IR section of the company's website for three months. Before we begin, please note that during today's call, management will make various forward-looking statem ...

Core Viewpoint - Polyrizon Ltd., a pre-clinical-stage biotechnology company, has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission [1] Company Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a hydrogel-based shield in the nasal cavity to protect against viruses and allergens [3] - The company's proprietary technology, Capture and Contain TM (C&C), utilizes naturally occurring building blocks to form a barrier in the nasal cavity, potentially acting as a "biological mask" [3] - Polyrizon is also developing its Trap and Target ™ (T&T) technology, focused on the nasal delivery of active pharmaceutical ingredients (APIs), which is currently in an earlier stage of pre-clinical development [3] Report Availability - The Annual Report on Form 20-F is accessible on the SEC's website and Polyrizon's Investor Relations website, with shareholders able to request copies free of charge [2]

Market Overview - The U.S. stock market experienced cautious trading and moderate volatility on March 25, 2026, as investors balanced anticipation of tech earnings with concerns over persistent "higher-for-longer" interest rates [1] - Major indexes closed in negative territory, with the Dow Jones Industrial Average (DJI) down approximately 201 points (0.51%), the S&P 500 (SPX) declining by 0.27%, and the Nasdaq Composite (IXIC) down 0.18% [2] Volatility and Investor Sentiment - Volatility remained elevated, with the CBOE Volatility Index (VIX) increasing, as investors hesitated to make bold bets ahead of significant earnings reports [3] Nvidia's Performance - Nvidia (NVDA) reported quarterly results that exceeded Wall Street expectations, leading to a surge in after-hours trading; the company announced a 10-for-1 stock split and a significant increase in its quarterly dividend [4] - Nvidia's strong performance positively impacted other AI-related companies, including Microsoft (MSFT), Alphabet (GOOGL), and Amazon (AMZN), although gains were mostly realized in after-hours trading [5] Retail Sector Analysis - Target (TGT) shares fell over 7% after reporting a decline in comparable sales and issuing a cautious outlook, citing a "challenging consumer environment" [6] - Conversely, TJX Companies (TJX) saw its stock price rise after beating earnings estimates and raising its full-year guidance, indicating a shift towards discount-oriented retail models [7] Federal Reserve Insights - The FOMC minutes revealed Federal Reserve officials' concerns about inflation, indicating a willingness to tighten policy further if inflation risks materialize, which pressured growth-oriented stocks [8] Other Notable Movers - Lululemon (LULU) dropped nearly 7% following the departure of its Chief Product Officer, while Moderna (MRNA) gained ground due to progress on a bird flu vaccine [9] Upcoming Market Events - Market participants are anticipating the release of weekly initial jobless claims and the preliminary reading of the U.S. Manufacturing PMI, which will be critical for assessing the labor market and potential rate cuts by the Federal Reserve [10]

Core Viewpoint - FibroBiologics, Inc. has announced a 1-for-20 reverse stock split to comply with Nasdaq listing requirements and attract broader investor interest, effective March 30, 2026 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from 70,256,883 to approximately 3,512,845 shares [1]. - The reverse stock split was approved by stockholders on February 20, 2026, allowing the Board of Directors to implement it [2]. - No fractional shares will be issued; any resulting fractional shares will be rounded up to the nearest whole share [3]. Group 2: Impact on Shareholders - The reverse stock split will not alter any stockholder's percentage ownership interest in the company, except for adjustments related to fractional shares [3]. - The number of shares available under the company's equity incentive plans and the exercise price of outstanding stock options will be proportionately adjusted [3]. Group 3: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells, holding over 270 patents [5]. - The company is engaged in various clinical pathways, including wound healing, multiple sclerosis, and cancer [5].